|
1
|
Cronin KA, Scott S, Firth AU, Sung H,
Henley SJ, Sherman RL, Siegel RL, Anderson RN, Kohler BA, Benard
VB, et al: Annual report to the nation on the status of cancer,
part 1: National cancer statistics. Cancer. 128:4251–4284. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mottet N, van den Bergh RCN, Briers E, Van
den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N,
Gandaglia G, Gillessen S, et al: EAU-EANM-ESTRO-ESUR-SIOG
guidelines on prostate cancer-2020 update. Part 1: Screening,
diagnosis, and local treatment with curative intent. Eur Urol.
79:243–262. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cornford P, van den Bergh RCN, Briers E,
Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N,
Gandaglia G, Gillessen S, et al: EAU-EANM-ESTRO-ESUR-SIOG
guidelines on prostate cancer. Part II-2020 update: Treatment of
relapsing and metastatic prostate cancer. Eur Urol. 79:263–282.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liesenfeld L, Kron M, Gschwend JE and
Herkommer K: Prognostic factors for biochemical recurrence more
than 10 years after radical prostatectomy. J Urol. 197:143–148.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Szerdahelyi P and Kása P: Histochemical
demonstration of copper in normal rat brain and spinal cord.
Evidence of localization in glial cells. Histochemistry.
85:341–347. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blockhuys S, Celauro E, Hildesjö C, Feizi
A, Stål O, Fierro-González JC and Wittung-Stafshede P: Defining the
human copper proteome and analysis of its expression variation in
cancers. Metallomics. 9:112–123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ge EJ, Bush AI, Casini A, Cobine PA, Cross
JR, DeNicola GM, Dou QP, Franz KJ, Gohil VM, Gupta S, et al:
Connecting copper and cancer: From transition metal signalling to
metalloplasia. Nat Rev Cancer. 22:102–113. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsvetkov P, Coy S, Petrova B, Dreishpoon
M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R,
Spangler RD, et al: Copper induces cell death by targeting
lipoylated TCA cycle proteins. Science. 375:1254–1261. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Y, Liu K, Shen K, Xiao J, Zhou X,
Cheng Q, Hu L, Fan H, Ni P, Xu Z, et al: A novel risk model
construction and immune landscape analysis of gastric cancer based
on cuproptosis-related long noncoding RNAs. Front Oncol.
12:10152352022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park A, Lee J, Mun S, Kim DJ, Cha BH, Moon
KT, Yoo TK and Kang HG: Identification of transcription factor YY1
as a regulator of a prostate cancer-specific pathway using
proteomic analysis. J Cancer. 8:2303–2311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ulitsky I: Evolution to the rescue: Using
comparative genomics to understand long non-coding RNAs. Nat Rev
Genet. 17:601–614. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tan YT, Lin JF, Li T, Li JJ, Xu RH and Ju
HQ: LncRNA-mediated posttranslational modifications and
reprogramming of energy metabolism in cancer. Cancer Commun (Lond).
41:109–120. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li C, Hu J, Hu X, Zhao C, Mo M, Zu X and
Li Y: LncRNA SNHG9 is a prognostic biomarker and correlated with
immune infiltrates in prostate cancer. Transl Androl Urol.
10:215–226. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang N, Meng X, Mi H, Chi Y, Li S, Jin Z,
Tian H, He J, Shen W, Tian H, et al: Circulating lncRNA XLOC_009167
serves as a diagnostic biomarker to predict lung cancer. Clin Chim
Acta. 486:26–33. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chao Y and Zhou D: lncRNA-D16366 is a
potential biomarker for diagnosis and prognosis of hepatocellular
carcinoma. Med Sci Monit. 25:6581–6586. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Chen W, Lian J, Zhang H, Yu B,
Zhang M, Wei F, Wu J, Jiang J, Jia Y, et al: The lncRNA PVT1
regulates nasopharyngeal carcinoma cell proliferation via
activating the KAT2A acetyltransferase and stabilizing HIF-1α. Cell
Death Differ. 27:695–710. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghildiyal R, Sawant M, Renganathan A,
Mahajan K, Kim EH, Luo J, Dang HX, Maher CA, Feng FY and Mahajan
NP: Loss of long noncoding RNA NXTAR in prostate cancer
augments androgen receptor expression and enzalutamide resistance.
Cancer Res. 82:155–168. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang X, Guo S, Xu M, Ma B, Liu R, Xu Y
and Zhang Y: TFAP2C-mediated lncRNA PCAT1 inhibits ferroptosis in
docetaxel-resistant prostate cancer through c-Myc/miR-25-3p/SLC7A11
signaling. Front Oncol. 12:8620152022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wen S, Wei Y, Zen C, Xiong W, Niu Y and
Zhao Y: Long non-coding RNA NEAT1 promotes bone metastasis of
prostate cancer through N6-methyladenosine. Mol Cancer. 19:1712020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hung CL, Wang LY, Yu YL, Chen HW,
Srivastava S, Petrovics G and Kung HJ: A long noncoding RNA
connects c-Myc to tumor metabolism. Proc Natl Acad Sci USA.
111:18697–18702. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang
B, Dong Q, Jiang N, Flores-Morales A, Chang C and Niu Y: LncRNA
PCAT1 activates AKT and NF-κB signaling in castration-resistant
prostate cancer by regulating the PHLPP/FKBP51/IKKα complex.
Nucleic Acids Res. 47:4211–4225. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chade DC, Shariat SF, Cronin AM, Savage
CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG,
Van Poppel H, et al: Salvage radical prostatectomy for
radiation-recurrent prostate cancer: A multi-institutional
collaboration. Eur Urol. 60:205–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Molina-Barrera ÁM, Ramos-Ulloa JG,
Becerra-Méndez LM, García-Valencia J, Varela-Ramírez R and
Silva-Chacón D: Predictors of biochemical recurrence after radical
prostatectomy at an oncology reference center in Colombia. Arch Esp
Urol. 74:656–663. 2021.(In Spanish). PubMed/NCBI
|
|
25
|
Tilki D, Preisser F, Graefen M, Huland H
and Pompe RS: External validation of the European association of
urology biochemical recurrence risk groups to predict metastasis
and mortality after radical prostatectomy in a European cohort. Eur
Urol. 75:896–900. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mengual L: Molecular technology to
optimize the use of biomarkers in the clinic. Arch Esp Urol.
75:103–112. 2022.(In Spanish). PubMed/NCBI
|
|
27
|
Hristova VA and Chan DW: Cancer biomarker
discovery and translation: Proteomics and beyond. Expert Rev
Proteomics. 16:93–103. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie J, Yang Y, Gao Y and He J:
Cuproptosis: Mechanisms and links with cancers. Mol Cancer.
22:462023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goyal B, Yadav SRM, Awasthee N, Gupta S,
Kunnumakkara AB and Gupta SC: Diagnostic, prognostic, and
therapeutic significance of long non-coding RNA MALAT1 in cancer.
Biochim Biophys Acta Rev Cancer. 1875:1885022021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Z, Ma Y, Guo X, Du Y, Zhu Q, Wang X
and Duan C: FDX1 can impact the prognosis and mediate the
metabolism of lung adenocarcinoma. Front Pharmacol. 12:7491342021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsvetkov P, Detappe A, Cai K, Keys HR,
Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, et al:
Mitochondrial metabolism promotes adaptation to proteotoxic stress.
Nat Chem Biol. 15:681–689. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Solmonson A, Faubert B, Gu W, Rao A,
Cowdin MA, Menendez-Montes I, Kelekar S, Rogers TJ, Pan C, Guevara
G, et al: Compartmentalized metabolism supports midgestation
mammalian development. Nature. 604:349–353. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ji L, Zhao G, Zhang P, Huo W, Dong P,
Watari H, Jia L, Pfeffer LM, Yue J and Zheng J: Knockout of MTF1
inhibits the epithelial to mesenchymal transition in ovarian cancer
cells. J Cancer. 9:4578–4585. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Masisi BK, El Ansari R, Alfarsi L, Rakha
EA, Green AR and Craze ML: The role of glutaminase in cancer.
Histopathology. 76:498–508. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luo JP, Wang J and Huang JH: CDKN2A is a
prognostic biomarker and correlated with immune infiltrates in
hepatocellular carcinoma. Biosci Rep. 41:BSR202111032021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang H, Cui B, Zhou Y, Wang X, Wu W, Wang
Z, Dai Z, Cheng Q and Yang K: B2M overexpression correlates with
malignancy and immune signatures in human gliomas. Sci Rep.
11:50452021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Z, Chen J, Ren D, Zhang J, Yang Y,
Zhang H, Mao B and Ma H: EPHA5 mutations predict survival after
immunotherapy in lung adenocarcinoma. Aging (Albany NY).
13:598–618. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang G, Xu D, Zhang Z, Li X, Shi J, Sun J,
Liu HZ, Li X, Zhou M and Zheng T: The pan-cancer landscape of
crosstalk between epithelial-mesenchymal transition and immune
evasion relevant to prognosis and immunotherapy response. NPJ
Precis Oncol. 5:562021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tsang T, Posimo JM, Gudiel AA, Cicchini M,
Feldser DM and Brady DC: Copper is an essential regulator of the
autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell
Biol. 22:412–424. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shanbhag VC, Gudekar N, Jasmer K,
Papageorgiou C, Singh K and Petris MJ: Copper metabolism as a
unique vulnerability in cancer. Biochim Biophys Acta Mol Cell Res.
1868:1188932021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Denoyer D, Pearson HB, Clatworthy SA,
Smith ZM, Francis PS, Llanos RM, Volitakis I, Phillips WA, Meggyesy
PM, Masaldan S and Cater MA: Copper as a target for prostate cancer
therapeutics: Copper-ionophore pharmacology and altering systemic
copper distribution. Oncotarget. 7:37064–37080. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xie F and Peng F: Reduction in copper
uptake and inhibition of prostate cancer cell proliferation by
novel steroid-based compounds. Anticancer Res. 41:5953–5958. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Safi R, Nelson ER, Chitneni SK, Franz KJ,
George DJ, Zalutsky MR and McDonnell DP: Copper signaling axis as a
target for prostate cancer therapeutics. Cancer Res. 74:5819–5831.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huynh TT, van Dam EM, Sreekumar S, Mpoy C,
Blyth BJ, Muntz F, Harris MJ and Rogers BE: Copper-67-labeled
bombesin peptide for targeted radionuclide therapy of prostate
cancer. Pharmaceuticals (Basel). 15:7282022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bao JH, Lu WC, Duan H, Ye YQ, Li JB, Liao
WT, Li YC and Sun YP: Identification of a novel cuproptosis-related
gene signature and integrative analyses in patients with
lower-grade gliomas. Front Immunol. 13:9339732022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang G, Sun J and Zhang X: A novel
cuproptosis-related LncRNA signature to predict prognosis in
hepatocellular carcinoma. Sci Rep. 12:113252022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bian Z, Fan R and Xie L: A novel
cuproptosis-related prognostic gene signature and validation of
differential expression in clear cell renal cell carcinoma. Genes
(Basel). 13:8512022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ferreira JM, Dellê H, Camacho CP, Almeida
RJ, Reis ST, Matos YST, Lima AMR, Leite KRM, Pontes-Júnior J and
Srougi M: Indoleamine 2,3-dioxygenase expression in the prognosis
of the localized prostate cancer. Int Urol Nephrol. 52:1477–1482.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Woo SR, Corrales L and Gajewski TF: The
STING pathway and the T cell-inflamed tumor microenvironment.
Trends Immunol. 36:250–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Luo C, Chen J and Chen L: Exploration of
gene expression profiles and immune microenvironment between high
and low tumor mutation burden groups in prostate cancer. Int
Immunopharmacol. 86:1067092020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ren L, Yang X, Wang W, Lin H, Huang G, Liu
Z, Pan J and Mao X: A cuproptosis-related LncRNA signature:
Integrated analysis associated with biochemical recurrence and
immune landscape in prostate cancer. Front Genet. 14:10967832023.
View Article : Google Scholar : PubMed/NCBI
|
